RU2746754C2 - Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии - Google Patents

Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии Download PDF

Info

Publication number
RU2746754C2
RU2746754C2 RU2018135317A RU2018135317A RU2746754C2 RU 2746754 C2 RU2746754 C2 RU 2746754C2 RU 2018135317 A RU2018135317 A RU 2018135317A RU 2018135317 A RU2018135317 A RU 2018135317A RU 2746754 C2 RU2746754 C2 RU 2746754C2
Authority
RU
Russia
Prior art keywords
antibody
amino acid
seq
variable region
cdr2
Prior art date
Application number
RU2018135317A
Other languages
English (en)
Russian (ru)
Other versions
RU2018135317A (ru
RU2018135317A3 (enExample
Inventor
Ясуко Киносита
Юмико КАВАЙ
Тосиаки ЦУНЭНАРИ
Такахиро Исигуро
Мика ЭНДО
Юдзи САНО
Original Assignee
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики Кайся filed Critical Чугаи Сейяку Кабусики Кайся
Publication of RU2018135317A publication Critical patent/RU2018135317A/ru
Publication of RU2018135317A3 publication Critical patent/RU2018135317A3/ru
Application granted granted Critical
Publication of RU2746754C2 publication Critical patent/RU2746754C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2018135317A 2016-03-14 2017-02-24 Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии RU2746754C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-050095 2016-03-14
JP2016050095 2016-03-14
PCT/JP2017/007033 WO2017159287A1 (ja) 2016-03-14 2017-02-24 癌の治療に用いるための細胞傷害誘導治療剤

Publications (3)

Publication Number Publication Date
RU2018135317A RU2018135317A (ru) 2020-04-15
RU2018135317A3 RU2018135317A3 (enExample) 2020-06-29
RU2746754C2 true RU2746754C2 (ru) 2021-04-20

Family

ID=59851601

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018135317A RU2746754C2 (ru) 2016-03-14 2017-02-24 Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии

Country Status (15)

Country Link
US (3) US11072666B2 (enExample)
EP (1) EP3431102A4 (enExample)
JP (4) JP6175590B1 (enExample)
KR (2) KR20180116215A (enExample)
CN (2) CN109069640B (enExample)
AU (2) AU2017233658B2 (enExample)
BR (1) BR112018068363A2 (enExample)
CA (1) CA3016424A1 (enExample)
MX (2) MX2018010988A (enExample)
MY (1) MY196747A (enExample)
PH (1) PH12018501977A1 (enExample)
RU (1) RU2746754C2 (enExample)
SG (2) SG10202007025PA (enExample)
TW (3) TW202214700A (enExample)
WO (1) WO2017159287A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
KR20170017916A (ko) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (ja) * 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3431102A4 (en) * 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
JP7556687B2 (ja) 2017-02-24 2024-09-26 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
WO2019160007A1 (ja) * 2018-02-14 2019-08-22 中外製薬株式会社 抗原結合分子および組合せ
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
WO2020153467A1 (ja) * 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
CN114829408B (zh) 2019-12-20 2024-01-26 山东博安生物技术股份有限公司 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
AU2021207586A1 (en) * 2020-01-13 2022-07-21 Neoimmunetech, Inc. Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
MX2022013920A (es) * 2020-05-07 2022-11-30 Phanes Therapeutics Inc Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
BR112022025536A2 (pt) * 2020-06-19 2023-01-17 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antígeno de células anti-t para uso em combinação com o inibidor da angiogênese
CN115698072B (zh) * 2020-07-01 2023-07-04 山东博安生物技术股份有限公司 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
CN118878693A (zh) * 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CA3205422A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
WO2023045151A1 (en) * 2021-09-24 2023-03-30 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against gpc3 and uses thereof
CN116355097B (zh) * 2021-09-24 2023-11-14 浙江时迈药业有限公司 针对gpc3的抗体及其用途和组合物
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
TW202432596A (zh) * 2022-11-01 2024-08-16 大陸商上海齊魯製藥研究中心有限公司 針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
TW202506727A (zh) * 2023-04-10 2025-02-16 美商麥迪紐有限責任公司 優化的ｃｄ３抗原結合結構域
CN116949156B (zh) * 2023-09-19 2023-12-08 美迪西普亚医药科技(上海)有限公司 一种基于核酸变体的通用型检测人t细胞的分析方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2519669C2 (ru) * 2003-05-30 2014-06-20 Дженентек, Инк. Лечение антителами против vegf
WO2015046467A1 (ja) * 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2015046554A1 (ja) * 2013-09-30 2015-04-02 中外製薬株式会社 改変されたヘルパーファージを用いて抗原結合分子を作製する方法
WO2015156268A1 (ja) * 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
RU2570639C2 (ru) * 2009-08-29 2015-12-10 Эббви Инк Терапевтические dll4-связывающие белки

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
CS269411B1 (en) 1988-09-14 1990-04-11 Ales Manek Device for yearn's interruption
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
PL182089B1 (en) 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
WO1996026648A1 (en) 1995-02-28 1996-09-06 The Procter & Gamble Company Preparation of noncarbonated beverage products having superior microbial stability
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
NZ333650A (en) 1996-07-19 2000-02-28 Amgen Inc Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
AU750453B2 (en) 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
WO2000018806A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
JP2004511426A (ja) 2000-05-03 2004-04-15 ミュンヘン　バイオテク　アーゲー 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
EP1423431B1 (en) 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
EP1411118B1 (en) 2001-06-22 2008-09-03 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican-3 antibody
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
MXPA04007583A (es) 2002-02-11 2005-04-25 Genentech Inc Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno.
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
DOP2005000002A (es) 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006031825A2 (en) 2004-09-13 2006-03-23 Macrogenics, Inc. Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
EP1799718A1 (en) 2004-09-14 2007-06-27 National Institute for Biological Standards and Control (NIBSC) Vaccine
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
CA2595169A1 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
EP2824183B1 (en) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
US20090028854A1 (en) 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
WO2006132352A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
US20090258001A1 (en) 2006-06-06 2009-10-15 Paul Ponath Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
AU2008230795B2 (en) 2007-03-27 2014-05-29 Bioassets, Llc Constructs and libraries comprising antibody surrogate light chain sequences
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
KR20110047255A (ko) 2008-09-26 2011-05-06 로슈 글리카트 아게 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
NZ592611A (en) 2008-10-10 2013-01-25 Emergent Product Dev Seattle A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
DE202008016028U1 (de) 2008-12-04 2010-04-15 Melitta Haushaltsprodukte Gmbh & Co. Kg Behälter zur Aufbewahrung von Gegenständen
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
MA33256B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
AU2010336277B2 (en) 2009-12-25 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Kirin Co., Ltd. Modified antibody composition
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US20140080153A1 (en) 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
IN2014MN02293A (enExample) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
CN104520331B (zh) 2012-06-01 2018-09-07 美国政府(由卫生和人类服务部的部长所代表) 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
CA2889951C (en) 2012-11-02 2023-04-18 Zymeworks Inc. Crystal structures of heterodimeric fc domains
CN103833852A (zh) 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
KR20170017916A (ko) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3320773B9 (en) 2015-07-10 2023-10-11 Chugai Seiyaku Kabushiki Kaisha Mouse having human cd3 gene substituted for endogenous cd3 gene
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
WO2019220368A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2519669C2 (ru) * 2003-05-30 2014-06-20 Дженентек, Инк. Лечение антителами против vegf
RU2570639C2 (ru) * 2009-08-29 2015-12-10 Эббви Инк Терапевтические dll4-связывающие белки
WO2015046467A1 (ja) * 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2015046554A1 (ja) * 2013-09-30 2015-04-02 中外製薬株式会社 改変されたヘルパーファージを用いて抗原結合分子を作製する方法
WO2015156268A1 (ja) * 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AITZIBER BUQUE et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications, Oncoimmunology, 2015, vol.4, no.4, e1008814. *

Also Published As

Publication number Publication date
AU2017233658A1 (en) 2018-09-13
US11072666B2 (en) 2021-07-27
AU2017233658B2 (en) 2023-09-21
KR101834708B1 (ko) 2018-03-06
SG11201807936VA (en) 2018-10-30
MX2018010988A (es) 2019-01-21
US20250066503A1 (en) 2025-02-27
PH12018501977A1 (en) 2019-06-17
JP2022116257A (ja) 2022-08-09
JP7440569B2 (ja) 2024-02-28
AU2023266341A1 (en) 2023-12-07
MY196747A (en) 2023-05-03
WO2017159287A1 (ja) 2017-09-21
JPWO2017159287A1 (ja) 2018-03-22
KR20180116215A (ko) 2018-10-24
RU2018135317A (ru) 2020-04-15
CN109069640B (zh) 2023-10-03
CN117205314A (zh) 2023-12-12
JP6175590B1 (ja) 2017-08-02
TW202214700A (zh) 2022-04-16
JP2017214405A (ja) 2017-12-07
TW201735947A (zh) 2017-10-16
CA3016424A1 (en) 2017-09-21
RU2018135317A3 (enExample) 2020-06-29
US20210388110A1 (en) 2021-12-16
CN109069640A (zh) 2018-12-21
US20200048361A1 (en) 2020-02-13
TW202342540A (zh) 2023-11-01
EP3431102A4 (en) 2019-09-25
SG10202007025PA (en) 2020-08-28
BR112018068363A2 (pt) 2019-01-15
MX2023005645A (es) 2023-05-25
JP2024054340A (ja) 2024-04-16
EP3431102A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
JP7440569B2 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
RU2743464C2 (ru) Индуцирующий цитотоксичность терапевтический агент
US11660340B2 (en) Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) Method for enhancing humoral immune response
WO2020052542A1 (en) Single-domain antibodies against cll1 and constructs thereof
US11505599B2 (en) T cell receptor-like antibodies specific for Foxp3-derived peptides
JP2021513848A (ja) Ｌａｇ３に結合する治療用分子
US11254745B1 (en) Anti-CD4 antibodies
HK40102796A (en) Cell injury inducing therapeutic drug for use in cancer therapy
JP2026508096A (ja) 治療抗体
RU2812875C1 (ru) Индуцирующий цитотоксичность терапевтический агент
HK1258783B (en) Cell injury inducing therapeutic drug for use in cancer therapy
BR122024002974A2 (pt) Agentes anticâncer que compreendem um anticorpo biespecífico, composição farmacêutica e seu uso
TW201927336A (zh) 細胞毒性ｔ細胞耗竭用組成物
HK1258783A1 (en) Cell injury inducing therapeutic drug for use in cancer therapy
EA041830B1 (ru) БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО, СВЯЗЫВАЮЩЕЕ ГЛИПИКАН 3 И CD3ε (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ЕГО, И СПОСОБ ПОЛУЧЕНИЯ ЭТОГО АНТИТЕЛА